LUGPA helps to promote clinical trials to accelerate recruitment process and provide general information on how LUGPA’s independent urology groups can get involved. LUGPA is in no way involved with these trials, but merely providing a resource hub as a service to its members.  

Clinical Trials Now Enrolling:

New Clinical Trial For Metastatic Prostate Cancer

MEVPRO-1 is a Phase 3 randomized, open-label clinical trial to evaluate an investigational medicine taken orally by tablets called mevrometostat for men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed after treatment with abiraterone acetate (Zytiga®).

MEVPRO-1 will investigate whether mevrometostat in combination with enzalutamide is superior to either enzalutamide or docetaxel in prolonging radiographic progression-free survival in the mCRPC setting.

Investigational mevrometostat has the potential to be the first-in-class EZH2 inhibitor for prostate cancer.

For more clinical trials, please check back later. 

Questions? Please contact Kelsey Brooks at [email protected] or (312) 833-3467.